Skip to main content

Table 1 Patient characteristics. *P<0.05

From: Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study

Patient characteristics CBDCA + GEM (n = 65) CDDP + VNR (n = 17) P
Median age, years (range) 66 (43–79) 59 (33–70) 0.004*
Gender (%)    0.239
 Male 51 (78.4) 11 (64.7)  
 Female 14 (21.5) 6( 35.2)  
Surgical procedure (%)    0.874
 Lobectomy 61 (93.8) 16 (94.1)  
 Pneumonectomy 4 (6.1) 1 (5.8)  
ECOG performance status (%)   0.002*
 0 36 (55.3) 17 (100)  
 1 27 (41.5) 0  
 2 2 (3.0) 0  
Pathological stage (%)    0.532
 IB 3 (4.6) 0  
 IIA 3( 4.6) 1 (5.8)  
 IIB 27 (41.5) 4 (23.5)  
 IIIA 22 (33.8) 8 (47.0)  
 IIIB 10 (15.3) 4 (23.5)  
Histology (%)    0.185
 Adenocarcinoma 44 (67.6) 16 (94.1)  
 Squamous cell carcinoma 19 (29.2) 1( 5.8)  
 Large cell carcinoma 1 (1.5) 0  
 Others 1 (1.5) 0  
Lymph nodal status (%)    0.271
 N0 15 (23.0) 2 (11.7)  
 N1 22 (33.8) 4 (23.5)  
 N2 28 (43.0) 11 (47.5)  
Number of course    0.119
 1/2/3/4 2/9/5/49 2/0/3/12  
EGFR mutation (%)    0.626
 Negative/unknown 53 (81.5) 13 (76.4)  
 Positive 12 (18.4) 4 (23.5)  
ALK fusion (%)    0.301
 Negative/unknown 64(98.4) 16(94.1)  
 Positive 1(1.54) 1(5.8)